Novel approaches to neural and evolutionary computing in pharmaceutical formulation: Challenges and new possibilities

Future Medicinal Chemistry

Volumn 1, Issue 4, 2009, Pages 713-726

  Colbourn, Elizabeth A ^a   Rowe, Raymond C ^a  

^a Intelligensys Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL NEURAL NETWORK; BIOTECHNOLOGY; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RESEARCH; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; REVIEW; ROOM TEMPERATURE; TEMPERATURE SENSITIVITY;

ALGORITHMS; DRUG COMPOUNDING; MODELS, THEORETICAL; NEURAL NETWORKS (COMPUTER); SOFTWARE;

EID: 77953371536     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.57     Document Type: Review

References (93)

1. Tarassenko L. A Guide to Neural Computing Applications. Arnold, London, UK (1998).
2. Zadeh LA. Fuzzy sets. Information Control 8, 338-353 (1965).
3. Bossley KM. Neurofuzzy Modelling Approaches in System Identification. PhD Thesis, University of Southampton, UK (1997).
4. Kavli T. Learning Principles in Dynamic Control. Dr. Scient. Thesis, University of Oslo, Norway (1992).
5. Holland JH. Adaptation in Natural and Artificial Systems. The University of Michigan Press, Ann Arbor, MI, USA (1975).
6. Koza JR. Genetic Programming - on the Programming of Computers by Means of Natural Selection. MIT Press, Cambridge, MA, USA (1992).
7. Colbourn EA, Rowe RC. Data Mining Methods in Pharmaceutical Formulation. In Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery. Balakin K (Ed.). Wiley, London, UK (2009).
8. Verduin WH. Better Products Faster - A Practical Guide to Knowledge-Based Systems for Manufacturers. Irwin Professional Publishers, USA (1994).
9. Turkoglu M, Ozarslan R, Sakr A. Artificial neural network analysis of a direct compression tabletting study. Eur. J. Pharm. Biopharm. 41, 315-322 (1995).
10. Kesavan JG, Peck GE. Pharmaceutical granulation and tablet formulation using neural networks. Pharm. Dev. Technol. 1, 391-404 (1996).
11. Colbourn EA, Rowe RC. Modelling and optimization of a tablet formulation using neural networks and genetic algorithms. Pharm. Tech. Eur. 8(9), 46-55 (1996).
12. Rowe RC, Colbourn EA. Generating rules for tablet formulations. Pharm. Tech. Eur. 12(1), 24-27 (2000).
13. Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Application of artificial neural networks (ANN) in the development of solid dosage forms. Pharm. Dev. Technol. 2, 111-121 (1997).
14. Bourquin J. Schmidli H, van Hoogevest P, Leuenberger H. Comparison of artificial neural networks (ANN) with classical modeling technologies using different experimental designs and data from a galenical study on a solid dosage form. Eur. J. Pharm. Sci. 6, 287-300 (1998).
15. Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Advantages of artificial neural networks (ANNs) as alternative modeling technique for data sets showing non-linear relationships using data from a galenical study on a solid dosage form. Eur. J. Pharm. Sci. 7, 5-16 (1998).
16. Bourquin J, Schmidli H, van Hoogevest P, Leuenberger H. Pitfalls of artificial neural networks (ANN) modeling technique for data sets containing outlier measurements using a study of mixture properties of a direct compressed tablet dosage form. Eur. J. Pharm. Sci. 7, 17-28 (1998).
17. Plumb AP, Rowe RC, York P, Brown M. Optimization of the predictive ability of artificial neural network (ANN) models: a comparison of three ANN programs and four classes of training algorithm. Eur. J Pharm. Sci. 25, 395-405 (2005).
18. Shao Q, Rowe RC, York P. Comparison of neurofuzzy logic and neural networks in modeling experimental data of an immediate release tablet formulation. Eur. J. Pharm. Sci. 28, 394-404 (2006).
19. Rocksloh K, Rapp F-R, Abu Abed S et al. Optimization of crushing strength and disintegration time of a high dose plant extract tablet by neural networks. Drug Dev. Ind. Pharm. 25, 1015-1025 (1999).
20. Do QM, Dang GV, Le NQ. Drawing up and optimizing the formulation of Malumix tablets by an artificial intelligence system (CAD/Chem). Tap Chi Hoa Hoc 6, 16-19 (2000).
21. Chen U, Thosor S, Forbess R, Kemper, M, Rubinovitz RL, Shukla AJ. Prediction of drug content and hardness of intact tablets using artificial neural networks and near-infrared spectroscopy. Drug Dev. Ind. Pharm. 27, 623-631 (2001).
22. Sathe PM, Venitz J. Comparison of neural networks and multiple linear regression as dissolution predictors. Drug Dev. Ind. Pharm. 29, 349-355 (2003).
23. Lindberg NO, Colbourn EA. Use of artificial neural networks and genetic algorithms - experiences from a tablet formulation. Pharm. Tech. Eur. 16(5), 35-39 (2004).
24. Zolotariou R, Anwar J. Modelling properties of powders using artificial neural networks and regression: the case of limited data. J. Pharm. Pharmacol. 50(Suppl.), 190 (1998).
25. Sunada H, Bi Y. Preparation, evaluation and optimization of rapidly disintegrating tablets. Powder Technol. 122, 188-198 (2002).
26. Agatonovic-Kustrin S, Glass BD, Wisch MH, Alany RG. Prediction of a stable microemulsion formulation for the oral delivery of a combination of antitubercular drugs using ANN technology. Pharm. Res. 20, 1760-1765 (2003).
27. Mendyk A, Jachowicz R. Neural network as a decision support system in the development of pharmaceutical formulation - focus on solid dispersions. Exp. Syst. App. 28, 285-294 (2005).
28. Mendyk A, Jachowicz R. Unified methodology of neural analysis in decision support systems built for pharmaceutical technology. Exp. Syst. App. 32, 1124-1131 (2007).
29. Plumb AP, Rowe RC, York P, Doherty C. The effect of experimental design in the modeling of a tablet coating formulation using artificial neural networks. Eur. J. Pharm. Sci. 16, 281-288 (2002).
30. Plumb AP, Rowe RC, York P, Doherty C. Effect of varying optimization parameters in optimization by guided evolutionary simulated annealing (GESA) using a tablet film coat on an example formulation. Eur. J. Pharm. Sci. 18, 259-266 (2003).
31. Rowe RC, Woolgar CG. Neurofuzzy logic in tablet film coating formulation. Pharm. Sci. Technol. Today 2, 495-497 (1999).
32. Hussain AS, Yu X, Johnson RD. Application of neural computing in pharmaceutical product development. Pharm. Res. 8, 1248-1252 (1991).
33. Hussain AS, Shivanand P, Johnson RD. Application of neural computing in pharmaceutical product development: computer aided formulation design. Drug. Dev. Ind. Pharm. 20, 1739-1752 (1996).
34. Takahara J, Takayama K, Nagai T. Multiobjective simultaneous optimization technique based on an artificial neural network in sustained release formulations. J. Control. Release 49, 11-20 (1997).
35. Ebube JK, McCall TW, Chen Y, Meyer MC. Relating formulation variables to in vitro dissolution using an artificial neural network. Pharm. Dev. Technol. 2, 225-232 (1997).
36. Chen Y, McCall TW, Baichwal AR, Meyer MC. The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms. J. Control. Release 29, 33-41 (1999).
37. Chen Y, Jiao T, McCall TW, Baichwal AR, Meyer MC. Comparison of four artificial neural network software programs used to predict the in vitro dissolution of controlled release tablets. Pharm. Dev. Technol. 7, 373-379 (2002).
38. Rowe RC, Colbourn EA, Roskilly SJ. A comparison of data mining methodologies in modeling controlled release tablet formulations. Controlled Release Society Annual Meeting. Glasgow, UK (2003).
39. Takayama K, Morva A, Fujikawa M, Hattori Y, Obata Y, Nagai T. Formula optimization of theophylline controlled release tablet based on artificial neural networks. J. Control. Release 68, 175-186 (2000).
40. Wei X-H, Wu J-J, Liang WQ. Application of an artificial neural network in the design of sustained release dosage forms. Acta Pharm. Sinica 36, 690-694 (2001).
41. Do DQ, Rowe RC, York P. Modeling drug dissolution from controlled release products using genetic programming. Int. J. Pharm. 351, 194-200 (2008).
42. Sheng H, Wang P, Tu J-S, Yuan L, Pin Q-N. Applications of artificial neural networks to the design of sustained release matrix tablets. Chin. J. Pharm. 29, 352-354 (1998).
43. Zupancic Bozic D, Vrecar F, Kozjek F. Optimization of diclofenac sodium dissolution from sustained release formulations using an artificial neural network. Eur. J. Pharm. Sci. 5, 163-169 (1997).
44. Ibric S, Jovanivic M, Djuric Z, Parjcic J, Solomun L. The application of a generalized regression neural network in the modeling and optimization of aspirin extended release tablets with Eudragit RSPO as matrix substance. J. Control. Release 82, 213-222 (2002).
45. Ibric S, Jovanovic M, Djuric A et al. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L100 as matrix substance. Pharm. Sci. Tech. 4, 62-70 (2003).
46. Leane MM, Cumming I, Corrigan O. The use of artificial neural networks for the selection of the most appropriate formulation and processing variables in order to predict the in vitro dissolution of sustained release minitablets. Pharm. Sci. Tech. 4, 218-229 (2003).
47. Wu T, Pao W, Chen J, Shang R. Formulation optimization technique based on artificial neural network in salbutamol sulfate osmotic pump tablets. Drug Dev. Ind. Pharm. 26, 211-215 (2000).
48. Peh KK, Lim CP, Qwek SS, Khoti KH. Use of artificial networks to predict drug dissolution profiles and evaluation of network performance using similarity profile. Pharm. Res. 17, 1386-1398 (2000).
49. Qwek SS, Lim CP, Peh KK. Prediction of drug dissolution profiles using artificial neural networks. Int. J. Comp. Intel. Applic. 1, 187-292 (2001).
50. Goh WY, Lim CP, Peh KK, Subari K. Application of recurrent neural networks to prediction of drug dissolution profiles. Neural Comput. 10, 311-317 (2002).
51. Vaithiyalingam S, Zaghloul AA, Reddes IK, Khan MA. Artificial neural network and simplex optimization for mixing of aqueous coated beads to obtain controlled release formulations. Pharm. Tech. 24(6), 60-72 (2000).
52. Vaithiyalingam S, Khan MA. Optimization and characterization of controlled release multiparticulate beads formulated with a customized cellulose acetate butyrate dispersion. Int. J. Pharm. 234, 179-193 (2002).
53. Turkoglu M, Varol H, Celikok M. Tableting and stability evaluation of enteric-coated omeprazole pellets. Eur. J. Pharm. Biopharm. 57, 277-286 (2004).
54. Ghaffari A, Abdollahi H, Khoshayand MR, Soltani Bozchalooi I, Dadgar A, Rafiee- Tehrani M. Performance comparison of neural network training algorithms in modeling of bimodal drug delivery. Int. J. Pharm. 327, 126-138 (2006).
55. Pillay V, Danckwerts MP. Textural profiling and statistical optimization of crosslinked calcium-alginate-pectinate-cellulose acetophthalate gelisphere matrices. J. Pharm. Sci. 91, 2559-2570 (2002).
56. Takahara J, Takayama K, Isowa K, Nagai T. Multi-objective simultaneous optimization based on artificial neural network in a ketoprofen hydrogel formula containing σ-ethylmenthol as a percutaneous absorption enhancer. Int. J. Pharm. 158, 203-210 (1997).
57. Takayama K, Takahara J, Fujikawa M, Ichikawa H, Nagai T. Formula optimization based on artificial neural networks in transdermal drug delivery. J. Control. Release 62, 161-170 (1999).
58. Wu P-C, Obata Y, Fijukawa M, Li CJ, Higashiyama K, Takayama K. Simultaneous optimization based on artificial neural networks in ketoprofen hydrogel formula containing S-ethyl-3-burylcyclohexanol as a percutaneous absorption enhancer. J. Pharm. Sci. 90, 1004-1014 (2001).
59. Kandimalla KK, Kanikkannon N, Singh M. Optimization of a vehicle mixture for the transdermal delivery of melatonin using artificial neural networks and response surface method. J. Control. Release 61, 71-82 (1999).
60. Gasperlin M, Tusar L, Tusar M, Kristl J, Smid-Korbar J. Lipophilic semisolid emulsion systems. Viscoelastic behavior and prediction of physical stability by neural network modeling. Int. J. Pharm. 168, 243-254 (1998).
61. Gasperlin M, Tusar L, Tusar M, Smid-Korbar J, Zupan J, Kristl J. Viscosity prediction of lipophilic semisolid emulsion systems by neural network modeling. Int. J. Pharm. 196, 37-50 (2000).
62. Nguyen LMT, Dang, GV, Le TS. Optimization of the skin cream formulation containing Centella asiatica and Curcuma longa extracts. Tap Chi Hoa Hoc 1, 15-18 (2001).
63. Onuki Y, Hoshi M, Okabe H, Fujikawa M, Morishita M, Takayama K. Formulation optimization of photocrosslinked polyacrylic acid modified with 2-hydroxyethly methacrylate hydrogel as an adhesive for a dermatological patch. J. Control. Release 108, 331-340 (2005).
64. Richardson CJ, Mbanefo A, Aboofazeli R, Lawrence MJ, Barlow DJ. Prediction of phase behavior in microemulsion systems using artificial neural networks. J. Coll. Interface Sci. 187, 296-303 (1997).
65. Alany RG, Agatonovic-Kustrin S, Rodes T, Tucker IG. Use of artificial neural networks to predict quaternary phase systems from limited experimental data. J. Pharm. Biomed. Anal. 19, 443-452 (1999).
66. Agatonovic-Kustrin S, Alany RG. Role of genetic algorithms and artificial neural networks in predicting phase behavior of colloidal delivery systems. Pharm. Res. 18, 1049-1055 (2001).
67. Djekic L, Ibric S, Primorac M. The application of artificial neural networks in the prediction of microemulsion phase boundaries in PEG-8 caprylic/capric glycerides based systems. Int. J. Pharm. 361, 41-46 (2008).
68. Fan T, Takayama K, Hattori Y, Maitani Y. Formulation optimization of Paclitaxel carried by PEGylated emulsions based on artificial neural network. Pharm. Res. 21, 1692-1697 (2004).
69. Amani A, York P, Chrystyn H, Clark BJ, Do DQ. Determination of factors controlling the particle size in nanoemulsions using artificial neural networks. Eur. J. Pharm. Sci. 35, 42-51 (2008).
70. Subramanian N, Yajnik A, Ramachandra Murthy RS. Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes. AAPS Pharm. Sci. Tech. 5, 1-9 (2004).
71. Yuksel N, Turkoglu M, Baykara T. Modeling of the solvent evaporation method for the preparation of controlled release acrylic microspheres using neural networks. J. Microencapsul. 17, 541-551 (2000).
72. Surini S, Akiyama H, Morishita M, Nagai T, Takayama K. Release phenomena of insulin from an implantable device composed of a polyion complex of chitosan and sodium hyaluronate. J. Control. Release 90, 291-301 (2003).
73. Reis MAA, Sinisterra RO, Belchior JC. An alternative approach based on artificial neural networks to study controlled drug release. J. Pharm. Sci. 93, 418-428 (2004).
74. Simon L, Fernandes M. Neural networkbased prediction and optimization of estradiol release from ethylene-vinyl acetate membranes. Comp. Chem. Eng. 28, 2407-2419 (2004).
75. Lennox B, Montague GA, Frith AM, Gent C, Bevan, V, Industrial applications of neural networks - an investigation. J. Process Control 11, 497-507 (2001).
76. Murtoniemi E, Merkku P, Yliruusi J. Comparison of four different neural network training algorithms in modeling the fluidized bed granulation process. Lab. Microcomput. 12, 69-76 (1993).
77. Murtoniemi E, Yliruusi J, Kinnunen P, Merkku P, Leiviska K. The advantages by the use of neural networks in modeling the fluidized bed granulation process. Int. J. Pharm. 108, 155-164 (1994).
78. Mertoniemi E, Merkky P, Kinnunen P, Leiviska K, Ylirussi J. Effect of neural network topology and training end point in modeling the fluidized bed granulation process. Int. J. Pharm. 110, 101-108 (1994).
79. Panda RC, Zank J, Martin H. Modeling the droplet deposition behavior on a single particle in fluidized bed spray granulation process. Powder Technol. 115, 51-57 (2001).
80. Rantanen J, Rasanen E, Antikainen O, Mannermaa J-P, Yliruusi J. In-line moisture measurements during granulation with a four wavelength near-infrared sensor: an evaluation of process-related variables and a development non-linear calibration model. Chemometric Intel. Lab. Syst. 56, 51-58 (2001).
81. Shao Q, Rowe RC, York P. Data mining of fractured experimental data using neurofuzzy logic - discovering and integrating knowledge hidden in multiple formulation databases for a fluid-bed granulation process. J. Pharm. Sci. 97, 2091-2101 (2008).
82. Watano S, Takashima H, Miyanami K. Scale-up of agitation fludized bed granulation by neural networks. Chem. Pharm. Bull. 45, 1193-1197 (1996).
83. Watano S, Sato Y, Miyanami K. Application of a neural network to granulation scale-up. Powder Technol. 90, 153-159 (1997).
84. Inghelbrecht S, Remon J-P, Fernandes de Aguiar P et al. Instrumentation of a roll compactor and the evaluation of the parameter setting by neural networks. Int. J. Pharm. 148, 103-115 (1997).
85. Turkoglu M, Aydin I, Murray M, Sakr A. Modeling of a roller-compaction process using neural networks and genetic algorithms. Eur. J. Pharm. Biopharm. 48, 239-245 (1999).
86. Mansa R, Bridson RH, Greenwood RW, Barker H, Seville JPK. Using intelligent software to predict the effects of formulation and processing parameters on roller compaction. Powder Technol. 181, 217-225 (2008).
87. Walsh DE, Zaccori N. Predictive statistical process controls - a neural network approach to maximizing tablet yield. Pharm. Tech. Eur. 13(9), 46-53 (2001).
88. Dowell JA, Hussain A, Devone J, Young D. Artificial neural networks applied to the in vitro-in vivo correlation of an extendedrelease formulation: initial trials and experience. J. Pharm. Sci. 88, 154-160 (1999).
89. Parojcic J, Ibric S, Dhuric Z, Jovanivic M, Corrigan OI. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation. Eur. Pharm. J. 30, 264-272 (2007).
90. de Matas M, Shao Q, Silkstone VL, Chrystyn H. Evaluation of an in vitroin vivo correlation for nebulizer delivery using artificial neural networks . J. Pharm. Sci. 96, 3293-3303 (2007).
91. de Matas M, Shao Q, Richardson C, Chrystyn H. Evaluation of in vitro-in vivo correlations for dry powder inhaler delivery using artificial neural networks. Eur. J. Pharm. Sci. 33, 80-90 (2008).
92. Rees C. Neural Computing - Learning Solutions - User Survey. Department of Trade and Industry, London, UK (1996).
93. Rowe RC, Roberts RJ. Intelligent Software for Product Formulation. Taylor and Francis, London, UK (1998).